Expectant Management Versus Methotrexate for Tubal Ectopic Pregnancy with Low β-hCG Levels

Abstract

Introduction: Small tubal ectopic pregnancies with falling or low β-hCG present a choice between expectant management and single-dose methotrexate (MTX). Comparative success and tubal patency outcomes inform practice.
Methods: Systematic review of randomized and quasi-randomized trials comparing expectant management with MTX for β-hCG <1500 IU/L and no fetal cardiac activity. Primary outcome was need for additional intervention.
Results: Eight trials (n=1,250 women) were included. Expectant management success rate was 74% versus 89% for MTX (risk difference 15%). Additional intervention risk was higher with expectant management (22% vs. 8%). Tubal patency at 3 months did not differ significantly (68% vs. 73%). Side effects were minimal in both groups.
Discussion: MTX is more effective but involves drug exposure and follow-up. Expectant management spares MTX side effects and may be acceptable for women with declining β-hCG. Neither approach harms subsequent fertility.
Conclusions: MTX is superior to expectant management for resolving low-level tubal ectopic pregnancies, but expectant management is a reasonable alternative for declining β-hCG and patient preference for avoidance of medication.